27080-53-1

Usage

Uses

Used in Pharmaceutical Industry:
1H-BENZIMIDAZOLE, 4-METHOXYis used as a key intermediate in the synthesis of various pharmaceutical compounds for its unique chemical structure that can be modified to achieve desired therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-BENZIMIDAZOLE, 4-METHOXYserves as a building block for the creation of complex organic molecules, leveraging its reactive sites for further functionalization.
Used in Research and Development:
1H-BENZIMIDAZOLE, 4-METHOXYis utilized in research for studying the properties of benzimidazole derivatives and exploring their potential in new chemical reactions or as precursors to novel compounds.
Used in Dye Industry:
1H-BENZIMIDAZOLE, 4-METHOXYmay also be employed in the development of dyes, where its aromatic structure and methoxy substitution can influence color characteristics and application properties.

InChI:InChI=1/C8H8N2O/c1-11-7-4-2-3-6-8(7)10-5-9-6/h2-5H,1H3,(H,9,10)

Upstream product

• 64-18-6 formic acid 
• 37466-89-0 3-methoxybenzene-1,2-diamine 
• 141-53-7 sodium formate 
• 33235-48-2 N³-benzyl-4-methoxybenzimidazole 
• 64-19-7 acetic acid 
• 16554-45-3 2-methoxy-6-nitroaniline 
• 603-85-0 2-Amino-3-nitrophenol 

Downstream Products

• 67021-83-4 4-hydroxy-1H-benzimidazole 
• 1314324-75-8 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3,4-dimethylbenzenesulfonamide 
• 1314324-79-2 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3,4-dimethoxybenzenesulfonamide 
• 1314324-81-6 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3-chloro-4-methylbenzenesulfonamide 
• 1314324-84-9 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3-nitro-4-methylbenzenesulfonamide 
• 1314324-85-0 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3,5-dichloro-4-hydroxylbenzenesulfonamide 
• 1314324-88-3 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-4-trifluoromethoxybenzenesulfonamide 
• 1314324-90-7 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3-trifluoromethoxybenzenesulfonamide 
• 1314324-91-8 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3-fluoro-4-methylbenzenesulfonamide 
• 1314324-92-9 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3-fluoro-4-methoxybenzenesulfonamide 
• 1314324-95-2 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3-methyl-4-bromobenzenesulfonamide 
• 1314324-97-4 N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-3,4,5-trimethoxybenzenesulfonamide 
• 1314324-98-5 N-(4-methoxyphenyl)-(4-methoxy-1H-benzo[d]imidazole)-7-sulfonamide 
• 1314324-99-6 N-(3,4-dimethoxyphenyl)-(4-methoxy-1H-benzo[d]imidazole)-7-sulfonamide 

Relevant academic research and scientific papers

Entropy Versus Enthalpy Controlled Temperature/Redox Dual-Triggered Cages for Selective Anion Encapsulation and Release

New C3-symmetric imidazole ligands were designed with phosphine and phosphine oxide linkers (LP and LPO, respectively) to demonstrate a dual-triggered dynamic closed coordination cage. Both LP and LPO

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Deprotection of N-benzylbenzimidazoles and N-benzylimidazoles with triethylsilane and Pd/C

The benzyl group is a protecting group for benzimidazoles and imidazoles that can survive acidic, basic, oxidizing, and reducing conditions. Deprotection, however, can require vigorous and potentially non-chemoselective methods. The triethylsilane–Pd/C reduction system is an exceptionally mild, convenient, and efficient method for deprotecting N-benzylbenzimidazoles that are unsubstituted at the 2- and 4-positions as well as suitably substituted N-benzylimidazoles.

Synthesis and antiproliferative evaluation of novel benzoimidazole- contained oxazole-bridged analogs of combretastatin A-4

A series of novel oxazole-bridged analogs of combretastatin A-4 bearing a benzo[d]-imidazole as B ring were synthesized and evaluated for antiproliferative activities against five human cancer cell lines. Among all the synthesized compounds, the N-unsubstituted benzoimidazole analog 5 and the analogs 6b, 7a and 7b with a small hydrophobic group on nitrogen atom of benzoimidazole ring were identified as the most potent inhibitors of tumor cell growth with IC50 values at nanomolar levels (5, IC50 = 8.4 nM, HT29; 6b, 7a, 7b, IC50 = 9.6 nM, 3.8 nM, 3.0 nM, A549). In a murine H22 tumor xenograft model, compound 5 exhibited significant antitumor activity. The binding mode of compound 5 in the colchicine binding site of tubulin was probed.

Synthesis and cytotoxic evaluation of N-(4-methoxy-1H-benzo[d]imidazol-7- yl)-arylsulfonamide and N-aryl-(4-methoxy-1H-benzo[d]imidazol)-7-sulfonamide analogs of combretastatin A-4

Two series of novel benzoimidazole sulfonamides as combretastatin A-4 analogs were synthesized. The cytotoxicities of the title compounds were evaluated against five different cancer cell lines. Among the tested compounds, four compounds displayed cytotoxicities against the HCT8 cell line. Compound 6a has shown the strongest potency against the tested human tumor cell lines with an IC50 value ranging from submicromolar to micromolar level.